- Record: found
- Abstract: found
- Article: not found
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Thomas M Habermann
1 ,
Edie A Weller ,
Vicki A Morrison ,
Randy D Gascoyne ,
Peter A Cassileth ,
Jeffrey B Cohn ,
Shaker R Dakhil ,
Bruce Woda ,
Richard I Fisher ,
Bruce A Peterson ,
Sandra J Horning
Jul 01 2006
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To address early and late treatment failures in older patients with diffuse large B-cell lymphoma (DLBCL), we designed a two-stage randomized trial of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP (R-CHOP), with a second random assignment to maintenance rituximab (MR) or observation in responding patients.